The 2021 US IPO market continues to break records. 20 IPOs went public this past week, the most in a single week since the year 2000. New filers have slowed ahead of the August lull, with just one IPO submitting an initial filing. Three issuers postponed, citing either volatility or market conditions: vehicle battery maker Clarios International (BTRY), specialty...read more
Rani Therapeutics, which develops ingestible capsules for oral dosing of medication, raised $73 million by offering 6.7 million shares at $11, below the range of $14 to $16. Rani Therapeutics is a clinical stage biotherapeutics company advancing technologies to enable the development of orally administered biologics, which it believes has the potential to transform medicine and...read more
Rani Therapeutics, which develops ingestible capsules for oral dosing of medication, announced terms for its IPO on Monday. The San Jose, CA-based company plans to raise $100 million by offering 6.7 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Rani Therapeutics would command a fully diluted market value of $724 million. Rani Therapeutics...read more
Rani Therapeutics, which develops ingestible capsules for oral dosing of medication, filed on Friday with the SEC to raise up to $100 million in an initial public offering. Rani Therapeutics is a clinical stage biotherapeutics company advancing technologies to enable the development of orally administered biologics, which they believe have the potential to transform medicine and...read more
US IPO Weekly Recap: Biotechs pop and Robinhood flops in a record 20 IPO week
The 2021 US IPO market continues to break records. 20 IPOs went public this past week, the most in a single week since the year 2000. New filers have slowed ahead of the August lull, with just one IPO submitting an initial filing. Three issuers postponed, citing either volatility or market conditions: vehicle battery maker Clarios International (BTRY), specialty...read more
Oral capsule developer Rani Therapeutics prices IPO well below the range at $11
Rani Therapeutics, which develops ingestible capsules for oral dosing of medication, raised $73 million by offering 6.7 million shares at $11, below the range of $14 to $16. Rani Therapeutics is a clinical stage biotherapeutics company advancing technologies to enable the development of orally administered biologics, which it believes has the potential to transform medicine and...read more
Oral capsule developer Rani Therapeutics sets terms for $100 million IPO
Rani Therapeutics, which develops ingestible capsules for oral dosing of medication, announced terms for its IPO on Monday. The San Jose, CA-based company plans to raise $100 million by offering 6.7 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Rani Therapeutics would command a fully diluted market value of $724 million. Rani Therapeutics...read more
Oral capsule developer Rani Therapeutics files for a $100 million IPO
Rani Therapeutics, which develops ingestible capsules for oral dosing of medication, filed on Friday with the SEC to raise up to $100 million in an initial public offering. Rani Therapeutics is a clinical stage biotherapeutics company advancing technologies to enable the development of orally administered biologics, which they believe have the potential to transform medicine and...read more